Tag: CAMT

Blue Horseshoe: Even More New Cannabis Stocks

Before we get started this morning, we’d like to welcome our newest readers. If you’re just joining us, you’ve missed an awful lot, as the gains we’ve seen in 2014 have already wowed us beyond belief, but not to worry- We intend to keep this freight train moving full speed ahead! We’ll continue to work hard at bringing you advance warning on chances for rapid-strike profits, from sub-pennies to big boards, options trading and more! Without further ado, let’s jump into a brand new week of action.

United Treatment Centers, Inc. UTRM

We hope that everyone has UTRM on their radar this morning. It is a play with impressive momentum that we caught off of our scanner on Friday.

After opening at .0045, UTRM shot up to .0082 (+82%). It dipped back to .0067 in the afternoon, before making another push to a new high of .0088 (+31%), bringing cumulative intraday gains to 113% The overall move from the low to the high was 96%

UTRM traded over a billion shares last week, and appears to be gapping up past Friday’s resistance at .0089. so we wouldn’t be surprised to see that momentum carry over into this week. We are placing UTRM on high alert for that reason, as well as its entry into the pot sector.

Per a recent PR, UTRM has a new marijuana-related website coming out on the 28th, so we’ll be waiting to take a look at the finished product.

Newcomers to the Marijuana Sector

Due to the extreme gains we’ve seen from so many companies that have chosen to take advantage of recent hysterical trend toward everything cannabis, we have another couple stocks to throw into the mix.

G&S Minerals, Inc. GSML

GSML recently filed a statement of conversion with the Colorado Secretary of State, noting its intent to change its name to Cannabis Holdings, Inc. effective April 1st.

We are going to want to tack this symbol onto our marijuana stock watchlist as GSML attempts to make the transition into the pot sector. We’ll also we on the lookout for further updates regarding the specific direction the company takes.

Supreme Pharmaceuticals, Inc. SPRWF

SPRWF woke up from the dead on news that it too would pursue a place in the medical marijuana arena. Friday the stock shot up significantly, and looks like it wants to gap up again this morning.

Chasing runners of this magnitude can be a risky prospect, so remember, the eventual pullback that is bound to happen at some point, will often give rise to one or more substantial bounce opportunities.

CALGARY, ALBERTA, Mar 24, 2014 (Marketwired via COMTEX) — Supreme Pharmaceuticals Inc. (the “Company”) (TSX VENTURE: SL)(OTCBB: SPRWF) is pleased to announce that the Company has signed a conditional agreement with an arms-length South Okanagan-based company, whereby the Company has the option to purchase its producing medical marijuana business for up to twelve months for the sum of $1,000,000, payable in cash and shares, subject to regulatory approval. The Company is currently in a 10-business day due diligence period and if satisfied, Supreme will make a $100,000 option payment.

Side Notes:
Plays that did well last week that we want to continue to monitor: MNGA, and PBR (May $12 Calls)

Extended Watchlist:
ORFG, ICLD, IDN, HEB, CAMT, PAL, CREG, UBIC

Blue Horseshoe Stocks: Pot Stocks Still Trending

Perhaps some of you were wondering why we went out of our way to re-affirm our interest in pot stocks yesterday. Our latest favorite sector provided a quick answer to that, as the uptrends continued for most of these plays. Once again we remind our readers that this up-and-coming market sector is bound to be one of the biggest stories of the year, and so far there’s no end in sight.

Alternative Energy Partners, Inc. AEGY

Our coverage of this medical marijuana stock in yesterday’s newsletter came just in the nick of time. The stock had been heating up in the previous session and did not disappoint, touching a low of .0036 before surging to a high of .0065. That marks an intraday gain of 81% on almost a billion shares traded (Roughly 9x the 3mo. average), and was a strong enough performance to land us atop the Penny Stock Rumble, an honor we’re no strangers to receiving:

The stock looks like it wants to gap up again this morning, so we;ll be watching AEGY diligently today.

Other Winning Cannabis Calls

Along with our reminder to continue paying attention to all marijuana-related stocks yesterday, we included a list of several of the more notable candidates, and of that list most of them saw substantial gains.

EAPH –  Daily Range: .0165-.0243 –  Max Gain: 47%

CBIS – Daily Range: .146-.26 – Max Gain: 78%

MJNA – Daily Range: .3151-.40 – Max Gain: 27%

HEMP – Daily Range: .059-.071 –  Max Gain: 20%

SKTO – Daily Range: .024-.0349 – Max Gain: 45%

ERBB – Daily Range: .012-.0147- Max Gain: 23%

TRTC – Daily Range: .385-.485 – Max Gain: 26%

Those are just a few of the opportunities that were available, as you can see from the following scan of yesterday’s most active OTC stocks. The vast majority were marijuana-related, as the “Green Rush” saw new life breathed into it once again:

Central Wireless, Inc. CWIR

To add a new cannabis play to our spectrum this morning, we are looking at CWIR. We noticed that this stock has been running over the past couple of sessions on greatly increased volume, and is going to be one that we want to follow closely.

Extended Watchlist:
AKS, ARIA, CTIC, CAMT, ADMP, TXMD,

CNAT, GOGO, UNIS, CAMT & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.

SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.

GOGO, Inc. GOGO

We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.

Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.

ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.

Unilife Corp. UNIS

UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.

YORK, Pa., Dec. 2, 2013 /PRNewswire/ — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.

Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.


Camtek, Ltd. CAMT

Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%

Cheers to anyone who was able to take advantage of those very timely alerts!

Extended Watchlist:
IACH, OMED, ETRM, FRO, DGLY, NAVB